Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 11.54% is 30% above its 5-year average of 8.85%, around the middle of its 5-year range (0.00%–26.25%).
As of the fiscal period ended Friday, July 31, 2026. 2.94% below its 12-month average of 11.89%.
Reported quarterly debt to assets ratio; no daily interpolation. Q3 FY2026 (2026-07-31): 11.54%.
DEBT TO ASSETS RATIO
11.54%
DEBT TO ASSETS RATIO AVG TTM
11.89%
DEBT TO ASSETS RATIO AVG 3Y
10.49%
DEBT TO ASSETS RATIO AVG 5Y
8.85%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-2.94%
CURRENT VS 3Y AVG
+10.02%
CURRENT VS 5Y AVG
+30.32%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 536 covered companies
CURRENT VS SECTOR MEDIAN
+11439.53%
vs the sector median at left
enGene Holdings Inc.
Market Cap
$122.26M
Debt to Assets Ratio
11.54%
TTM Avg
11.89%
3Y Avg
10.49%
5Y Avg
8.85%
Market Cap
$119.80M
Debt to Assets Ratio
0.09%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$119.09M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$118.52M
Debt to Assets Ratio
0.19%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$116.59M
Debt to Assets Ratio
0.09%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$116.30M
Debt to Assets Ratio
0.21%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$115.66M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$114.76M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| enGene Holdings Inc. (ENGN) | $122.26M | 11.54% | 11.89% | 10.49% | 8.85% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $119.80M | 0.09% | N/A | N/A | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $119.09M | 0.01% | N/A | N/A | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.52M | 0.19% | N/A | N/A | N/A |
| Genelux Corporation (GNLX)vs › | $116.59M | 0.09% | N/A | N/A | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $116.30M | 0.21% | N/A | N/A | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $115.66M | 0.01% | N/A | N/A | N/A |
| Entera Bio Ltd. (ENTX)vs › | $129.39M | 0.02% | N/A | N/A | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $114.76M | 0.00% | N/A | N/A | N/A |
| Cibus, Inc. (CBUS)vs › | $129.76M | 0.10% | N/A | N/A | N/A |
Debt/Assets
11.5%
Debt/Equity
0.14
Current Ratio
10.21
Interest Coverage
-41.1x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-07-31 | 11.54% |
| 2026-04-30 | 10.85% |
| 2026-01-31 | 9.93% |
| 2025-10-31 | 14.36% |
| 2025-07-31 | 12.78% |
| 2025-04-30 | 9.51% |
| 2025-01-31 | 8.79% |
| 2024-10-31 | 8.04% |
| 2024-07-31 | 9.31% |
| 2024-04-30 | 9.02% |
| 2024-01-31 | 26.25% |
| 2023-10-31 | 11.24% |
| 2023-07-31 | 1.81% |
| 2023-04-30 | 0.34% |
| 2022-12-31 | 0.00% |
| 2022-10-31 | 24.47% |
| 2022-07-31 | 0.00% |
| 2022-04-30 | 0.00% |
| 2021-12-31 | 0.00% |
